Home / Sector / Healthcare Shares / Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Posted by
Laura Stewart
Author bio Laura Stewart is a Finance Editor at The Motley Fool, where she covers Australian and international equity markets. She joined the company in 2022, following a career transition from legal advisory work in Southeast Asia into the investment industry. Prior to her current editorial role, Laura spent three years as an Equity Analyst and Writer, producing investment research across the ASX, NYSE, and NASDAQ. Her coverage included small-cap growth companies, thematic investment ideas, and high-quality U.S.-listed businesses. Laura holds a Master of Applied Finance and brings additional expertise in accounting, taxation, and estate and wealth planning from her postgraduate studies. She also has a background in law and communications, which supports her analytical and reporting work in financial markets. Outside of work, she enjoys spending time in the Adelaide Hills with her flock of sheep. Education Laura holds a Bachelor of Laws, a Bachelor of Communication (Journalism), and a Bachelor of Commerce with majors in Accounting and Corporate Finance. In 2025, she completed a Master of Applied Finance at the University of Adelaide, receiving postgraduate awards in Accounting Concepts & Methods, Ethical Principles in Accounting & Finance, Real Estate Valuation & Investment, and Tax, Estate & Wealth Planning. Social media LinkedIn FYI – I am taking a break from social media at the moment, so this account isn’t active at the moment, but I will let you know when I rejoin. Favorite investment quote "Compound interest is the eighth wonder of the world. He who understands it, earns it... he who doesn't... pays it." — Albert Einstein
Published
| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imricor Medical Systems Inc (ASX: IMR) share price is in focus today after the company announced the commercial launch of its Interventional MR (iMR) lab solution in collaboration with global imaging leader Philips. This new combined solution is immediately available in CE-marked markets and is designed to support MR-guided cardiac interventions.

Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

What did Imricor Medical Systems report?

  • Commercial launch of a combined iMR lab solution with Philips.
  • The solution integrates Philips' 1.5T BlueSeal MR platform with Imricor's NorthStar®, Advantage-MR®, and other systems.
  • Includes Imricor's single-use catheters and interventional tools for cardiac procedures.
  • Available immediately in CE-marked markets; select configurations in the US now and more pending regulatory approval.
  • Scalable platform for potential expansion into new procedures and clinical areas.

What else do investors need to know?

The launch builds on Imricor's longstanding partnership with Philips, which began in 2012 with joint technology development. The iMR lab solution is designed specifically for cardiac electrophysiology and other interventional cardiac procedures, using MR-guided imaging for improved care.

This innovative, purpose-built approach aims to move MR imaging technology directly into the procedure room, making advanced interventions safer and more effective. The collaboration positions Imricor alongside a major industry player, broadening its reach and potential customer base.

What's next for Imricor Medical Systems?

Imricor plans to showcase the new iMR lab solution at the ESC Congress 2026 in Munich. The company expects further configurations to be launched in the United States and other geographies as regulatory clearances are achieved.

Management sees this launch as a foundation for future growth, with ambitions to expand the platform into new clinical areas beyond cardiac electrophysiology. The partnership with Philips could pave the way for increased adoption of MR-guided interventions globally.

Imricor Medical Systems share price snapshot

Over the past 12 months, Imricor shares have risen 39%, outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

| Aaron Bell

These two stocks have big upside.

Read more »

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

| Marc Van Dinther

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses

| Laura Stewart

Clarity Pharmaceuticals reported strong FY26 revenue growth, a wider loss, and progress towards commercialisation of its radiopharmaceutical pipeline.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend

| Laura Stewart

Clinuvel Pharmaceuticals reported its tenth straight profit, rising cash reserves, and steady dividend for FY2026.

Read more »

Man and woman sitting at table with the man looking a bit puzzled at his laptop.
Healthcare Shares

Should I buy CSL shares before the end of August?

| Grace Alvino

I think the company's earnings outlook is starting to look more encouraging.

Read more »

Female pharmacist smiles with a digital tablet.
Earnings Results

Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth

| James Mickleboro

The company reported double-digit revenue growth.

Read more »

Health professional working on his laptop.
Earnings Results

Mesoblast earnings: Strong revenue growth and operational milestones in FY26

| James Mickleboro

The biotech has reported a significant jump in revenue.

Read more »

Two lab workers fist pump each other.
Earnings Results

Ramsay Health Care FY26: Profit surges on transformation momentum

| James Mickleboro

The results show stronger profit growth, a higher dividend, and continued momentum in its transformation plans.

Read more »